Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing, and development of more than 100 companies, including twenty-seven which have reached valuations exceeding $1 billion. His seed and early-stage investments include Illumina (ILMN); Alnylam Pharmaceuticals (ALNY); Juno Therapeutics (JUNO); Sana Biotechnology (SANA), Unity Biotechnology (UBX); Sienna Biopharmaceuticals (SNNA); Vir Biotechnology(VIR); Agios Pharmaceuticals (AGIO); Sage Therapeutics (SAGE); GRAIL; Ikaria; Kythera Biopharmaceuticals (KYTH); Receptos (RCPT); Aviron (AVIR); Denali Therapeutics (DNLI); Prime Medicine; Beam Therapeutics (BEAM); NetBot; Bluebird Bio (BLUE); R2 Technology; XenoPort (XNPT); Caliper Life Sciences (CALP); Trubion Pharmaceuticals (TRBN); Adolor (ADLR); deCODE Genetics; Array BioPharma (ARRY); Editas (EDIT); IDUN Pharmaceuticals; Classmates.com; Hua Medicine; Fate Therapeutics (FATE); Rubius Therapeutics (RUBY); KSQ Therapeutics; WuxiNextCODE; and Everyday Learning Corporation.
Mr. Nelsen is a director of Vir Bio, GRAIL, Sana Biotechnology, Beam Therapeutics, Prime Medicine, Resilience, Lyell, RBNC, Revolution Healthcare Acquisition Corp., Denali Therapeutics, Karuna Therapeutics, insitro, Maze Therapeutics, Inc., and serves as Chairman of Hua Medicine, among others. He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and was a director of the National Venture Capital Association. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.
What is Robert Nelsen's net worth?
The estimated net worth of Robert Nelsen is at least $12.32 million as of February 15th, 2024. Mr. Nelsen owns 3,200,000 shares of Prime Medicine stock worth more than $12,320,000 as of December 5th. This net worth approximation does not reflect any other investments that Mr. Nelsen may own. Learn More about Robert Nelsen's net worth.
How do I contact Robert Nelsen?
Has Robert Nelsen been buying or selling shares of Prime Medicine?
Robert Nelsen has not been actively trading shares of Prime Medicine over the course of the past ninety days. Most recently, on Thursday, February 15th, Robert Nelsen bought 3,200,000 shares of Prime Medicine stock. The stock was acquired at an average cost of $6.25 per share, with a total value of $20,000,000.00. Following the completion of the transaction, the director now directly owns 3,200,000 shares of the company's stock, valued at $20,000,000. Learn More on Robert Nelsen's trading history.
Are insiders buying or selling shares of Prime Medicine?
In the last year, Prime Medicine insiders bought shares 4 times. They purchased a total of 3,093,300 shares worth more than $10,110,240.00. The most recent insider tranaction occured on August, 1st when Major Shareholder Arch Venture Partners Xii, Llc bought 3,030,300 shares worth more than $9,999,990.00. Insiders at Prime Medicine own 22.7% of the company.
Learn More about insider trades at Prime Medicine. Information on this page was last updated on 8/1/2025.
